Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,758 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A reply to "Correspondence Re: Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model".
Moldaver D, Hurry M, Evans WK, Cheema PK, Sangha R, Burkes R, Melosky B, Tran D, Boehm D, Venkatesh J, Walisser S, Orava E, Grima D. Moldaver D, et al. Among authors: tran d. Lung Cancer. 2021 Jan;151:110-111. doi: 10.1016/j.lungcan.2020.11.015. Epub 2020 Dec 2. Lung Cancer. 2021. PMID: 33323299 No abstract available.
Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies.
Rozenbaum MH, Garcia A, Grima D, Tran D, Bhambri R, Stewart M, Li B, Heeg B, Postma M, Masri A. Rozenbaum MH, et al. Among authors: tran d. Eur Heart J Qual Care Clin Outcomes. 2022 Aug 17;8(5):529-538. doi: 10.1093/ehjqcco/qcab031. Eur Heart J Qual Care Clin Outcomes. 2022. PMID: 33895806 Free PMC article. Clinical Trial.
Estimating the annual economic burden for the management of patients with transthyretin amyloid polyneuropathy in Spain.
Galan L, Gonzalez-Moreno J, Martínez-Sesmero JM, Muñoz-Beamud F, Santos-Rubio MD, Tran D, Lebeau P, Stewart M, Mallaina P, Tarilonte P, Peral C, Rozenbaum MH. Galan L, et al. Among authors: tran d. Expert Rev Pharmacoecon Outcomes Res. 2021 Oct;21(5):967-973. doi: 10.1080/14737167.2021.1900738. Epub 2021 Mar 24. Expert Rev Pharmacoecon Outcomes Res. 2021. PMID: 33724140 Free article.
Letter to the editor concerning the article: "An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy".
Salvo EM, Samjoo IA, Tran D, Cameron C. Salvo EM, et al. Among authors: tran d. Expert Opin Pharmacother. 2019 Aug;20(12):1527-1528. doi: 10.1080/14656566.2019.1620983. Epub 2019 May 24. Expert Opin Pharmacother. 2019. PMID: 31124724 No abstract available.
2,758 results